Detail akcie Kura Oncology online

Business Summary: Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Kura Oncology Inc revenues increased 25% to $67.5M. Net loss increased 60% to $278.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Discovery and development of precision medicines segment loss increase of 57% to $303.6M, United States segment loss increase of 57% to $303.6M.